ArriVent Biopharma
AVBP16.7300.12% ( +0.020 )
ArriVent Biopharma (AVBP)
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unm...
- Open
- 16.590
- High
- 17.760
- Low
- 16.490
- Prev. Close
- 16.710
- Volume
- 1.73M
- Turnover
- 29.52M
- Avg Price
- 17.045
- Bid/Ask Ratio
- 0.00%
- Amplitude
- 7.60%
- 52wk High
- 35.830
- Volume Ratio
- 3.06
- Turnover Ratio
- 5.39%
- 52wk Low
- 11.360
- Float Mkt Cap
- 537.14M
- Market CapUSD
- 824.92M
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -3.33
- EPSDynamic
- -3.79
- EPSStatic
- --
- BVPS
- 7.44
- P/B
- 2.25
- Circulating Supply
- 32.11M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 49.31M
- Min lot size
- 1
- Currency
- USD
ArriVent Biopharma Analyst Rating
View moreForecast & Rating
Oct 8, 2026Price forecast
$20.5622.87%
Forecast & RatingStrong buy
11analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Weekly Review ·
Weekly Recap | ArriVent Biopharma -40.82%, Phase 3 trial misses endpoint
- benzinga_article ·
Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday
- Yicai ·
Allist Slumps After Star Lung Cancer Drug Fails in Overseas Clinical Trial
- TradingView ·
HC Wainwright & Co. maintains Buy rating on ArriVent BioPharma, $27 price target
- MorningStar ·
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law
- PR Newswire ·
AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
